NeuroSense reported a 7.92-point ALS function gap with PrimeC, but will its Phase 3 trial confirm a real treatment benefit?
NeuroSense Therapeutics is using clinical and biomarker findings from its Phase 2b PARADIGM programme to refine the planned Phase 3 PARAGON trial of PrimeC. The published study reported encouraging long-term functional differences, but its six-month comparison was not statistically significant and the company faces substantial financing and listing pressures.
